SELLAS Life Sciences Group (SLS) Stock: Buy, Sell, or Hold?
SLS - SELLAS Life Sciences Group, Inc. Common Stock
$11.33
-0.98 (-7.96%)
▼
5d:
-5.43%
30d:
-14.3%
90d:
-24.37%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 1, 2026 at $11.33 · last confirmed Oct 1, 2026
Strength: 6.3/10
Get Alerted When SLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SLS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SLS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SLS is currently trading at $11.33, which is considered oversold relative to its 30-day fair value range of $11.48 to $13.85.
Technical Outlook: Technically, SLS is in a uptrend. The price is currently testing key support at $11.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: SLS scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $32.50 (+186.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SLS is in a uptrend. The price is currently testing key support at $11.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: SLS scores 85/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $32.50 (+186.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.48 -
$13.85
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
Protect Your Profits
Holding SLS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (85/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 186.8% below Wall St target ($32.50)
- CAUTION: Bottoming setup, but lagging the sector by 32% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$11.48 -
$13.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$11.06
Resistance Level
$12.53
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-113.30
Wall Street Target
$32.50
(+186.8%)
Revenue Growth (YoY)
-82.5%
Share & Embed Analysis
Last updated: October 02, 2026 7:09 AM ET
Data refreshes hourly during market hours. Next update: 8:09 AM
Data refreshes hourly during market hours. Next update: 8:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
Advanced SLS Option Strategies
Professional options setups generated by AI based on today's SLS price and gamma walls.
